BioSpace News Archive

L.A. Area Firms Will Debut Latest Digital Innovations for Transforming Healthcare

Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces financial results for the three and nine months ended September 30, 2019.

Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the quarter ended September 30, 2019 and provided an update on its business performance and strategic initiatives.

Revance Therapeutics, Inc., a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, announced that the company will participate in the Credit Suisse 28th Annual Healthcare Conference, in Scottsdale, AZ.

Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced financial results for the third quarter ended September 30, 2019.

Advanced CF program with single-ascending dose (SAD) clinical data presentation and continued enrollment and dosing in multiple-ascending dose (MAD) portion of Phase 1/2 trial

Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019

The Medicines Company announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science sessions at the American Heart Association Scientific Sessions 2019, November 16-18, in Philadelphia.

Inari Medical, Inc. announced the presentation of early outcomes from the ClotTriever Outcomes Registry using the ClotTriever Mechanical Thrombectomy System for treatment of acute and chronic lower extremity deep vein thrombosis Initial results for the first 50 patients were presented by principal investigator David J. Dexter, MD, a vascular surgeon at Sentara Healthcare in Norfolk, VA at the VIVA 2019 late-breaking clinical trials session held in Las Vegas, NV.